Merrimack's MM-121 misses primary endpoint, shares slide

Merrimack Pharmaceuticals' (MACK) MM-121 misses its PFS primary endpoint in a Phase 2 trial evaluating the treatment in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum-refractory advanced ovarian cancers.

Hazard Ratio was 1.

The company says "ongoing analysis of a pre-specified set of biomarkers mechanistically linked to ErbB3 signaling identified a potential subpopulation of patients benefiting from MM-121 treatment in combination with paclitaxel."

In the group receiving the combination therapy, there was "an overall increase in all grades of gastrointestinal toxicities." (PR)

MACK -12% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs